CEBPA mutations in MDS are uncommon but associated with shorter survival and an increased risk of AML transformation.

Adding venetoclax to hypomethylating agents increased composite remission but did not improve overall survival in HR-MDS.

Myelodysplastic syndromes (MDS) are a group of blood cancers that affect the bone marrow and can result in a low levels of blood cells. When MDS affects red blood cells, it can lead to anemia in some ...

Five people living with myelodysplastic syndromes (MDS) or in survivorship talk about their experiences with this serious and commonly misunderstood group of conditions. Myelodysplastic syndromes (MDS ...

Early low-dose lenalidomide significantly reduces mutational burden without increasing AML risk in non-transfusion-dependent del(5q) MDS.

Two abstracts presented at the 2024 American Society of Hematology Annual Meeting & Exhibition provided insight into MDS response to hypomethylating agents (HMAs). Patients with myelodysplastic ...

Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...

Myelodysplastic syndromes cause persistent exhaustion that affects both physical and mental well-being, making daily activities challenging even when anemia is treated. Establishing consistent sleep ...